BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34718847)

  • 1. Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.
    Wang B; He Z; Yu H; Ou Z; Chen J; Yang M; Fan X; Lin T; Huang J
    Cancer Immunol Immunother; 2022 Jun; 71(6):1507-1517. PubMed ID: 34718847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High mannose level in bladder cancer enhances type 1 fimbria-mediated attachment of uropathogenic
    Maalouf N; Gur C; Yutkin V; Scaiewicz V; Mandelboim O; Bachrach G
    Front Cell Infect Microbiol; 2022; 12():968739. PubMed ID: 36118038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits epidermal growth factor receptor signaling pathway activation and induces apoptosis in bladder cancer cells in vitro and in vivo.
    Chang L; Xiao W; Yang Y; Li H; Xia D; Yu G; Guo X; Guan W; Hu Z; Xu H; Zhuang Q; Ye Z
    Urol Oncol; 2014 Jan; 32(1):36.e11-8. PubMed ID: 23948182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
    Domingos-Pereira S; Sathiyanadan K; La Rosa S; Polák L; Chevalier MF; Martel P; Hojeij R; Derré L; Haefliger JA; Jichlinski P; Nardelli-Haefliger D
    Cancer Immunol Res; 2019 Apr; 7(4):621-629. PubMed ID: 30696629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous Injections of the Mannose-Sensitive Hemagglutination Pilus Strain of Pseudomonas aeruginosa Stimulate Host Immunity, Reduce Bladder Cancer Size and Improve Tumor Survival in Mice.
    Li T; Yang L; Fu SJ; Xiao EL; Yuan X; Lu JZ; Ma BL; Shi TK; Wang ZP
    Cell Biochem Biophys; 2015 Sep; 73(1):245-52. PubMed ID: 25724441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
    Derré L; Lucca I; Cesson V; Bohner P; Crettenand F; Rodrigues-Dias SC; Dartiguenave F; Masnada A; Teixeira-Pereira C; Benmerzoug S; Chevalier MF; Domingos-Pereira S; Nguyen S; Polak L; Schneider AK; Jichlinski P; Roth B; Nardelli-Haefliger D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer.
    Chin JL; Kadhim SA; Batislam E; Karlik SJ; Garcia BM; Nickel JC; Morales A
    J Urol; 1996 Sep; 156(3):1189-93. PubMed ID: 8709344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
    Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
    Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OncoTherad
    Reis IB; Tibo LHS; de Souza BR; Durán N; Fávaro WJ
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5025-5036. PubMed ID: 36322290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
    World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.